Cutting Edge Models for Alzheimer's Disease Research - 5xFAD Mouse Model
Alzheimer's Disease (AD) stands as one of the most pressing health challenges of our time, affecting millions of individuals worldwide. One of the critical hurdles in understanding this complex neurodegenerative disorder is the lack of suitable animal models that faithfully recapitulate the pathological features observed in human patients. One such Alzheimer's disease mouse model that has been at the forefront of AD research is the 5xFAD mouse model.
Developed in 2006 by Oakley et al., the 5xFAD mouse model represents a significant advancement in AD research. This transgenic mouse model harbors five familial AD mutations, namely three mutations in the human amyloid precursor protein (APP) gene and two mutations in the human presenilin 1 (PS1) gene. These mutations are associated with early-onset familial AD and lead to accelerated Aβ plaque formation in the brain.
Fig. 1 Immunohistochemical staining β-amyloid in the brain of the 5XFAD mouse. There is a significant accumulation of β-amyloid plaques in a number of brain regions including the cerebral cortex (CC), hippocampus (H), thalamus (T), and amygdala (A).1
With a wealth of research experience, Creative Biolabs can assist you in AD disease research. Besides constructing 5XFAD mouse models, we also provide other AD related research services. If you are interested in our services, please feel free to contact us for more details.
Our Services | Descriptions |
AD In Vitro Assay | Creative Biolabs provides diverse cell culture models, especially AD in vitro models, which are beneficial to better exploring the mechanisms of AD. We have established an advanced platform for Aβ aggregation assay and tau aggregation assay. We are committed to providing professional AD in vitro testing services to customers around the world. |
AD Animal Models | Creative Biolabs develops experimental animal models that recapitulate various aspects of the neuropathological features of AD. Our animal models of AD have been widely used to identify disease modifiers, causative agents, susceptibility genes, and for drug screening. |
AD Biomarker Assay | Creative Biolabs is the specialist provider of AD biomarker assays. We have a professional team of scientists to provide a comprehensive range of rapid AD biomarker assays through standard experimental procedures to meet the different needs of AD research. |
AD Modeling and Drug Efficacy Testing Service | We have developed a comprehensive range of AD animal models and primary neuronal culture models and assays to provide a variety of recognized testing protocols. We also help our clients validate and develop the most cost-effective experimental designs and protocols. |
Investigative Benefits of the 5xFAD Mouse Model
5xFAD mouse model has outstanding efficacy in that it progressively develops significant hallmarks of AD, including amyloid plaques, neurofibrillary tangles, neuronal loss, and cognitive deficits. There are main advantages of 5xFAD mouse models.
- Rapid and Robust Amyloid Pathology - The 5xFAD mice develop extensive Aβ plaques at a relatively young age, with plaque deposition starting as early as two months of age.
- Reproducibility and Consistency - The 5xFAD model displays consistent and predictable disease progression. This reproducibility ensures that results obtained from different cohorts are comparable and reliable.
- Behavioral and Cognitive Phenotypes - Alongside amyloid pathology, 5xFAD mice exhibit cognitive deficits and behavioral abnormalities reminiscent of AD symptoms, including impairments in spatial memory, learning, and synaptic plasticity, which closely resemble the cognitive decline observed in human patients.
- Accessibility and Wide Usage - A large number of published studies have examined various aspects of AD using this model. This widespread usage has led to the accumulation of a vast body of literature, enabling researchers to leverage existing knowledge and build upon previous findings.
In addition to mouse models, a number of research tools are also important used in AD research. You can browse the table below to see a list of our recommended products.
Cat. No | Product Name | Species Reactivity | Applications |
NAB-2011-ZP115 | Mouse Anti-β-Amyloid 1-42 Monoclonal Antibody (CBP2145) | Human | IHC; ELISA |
NAB-BA-P064 | Mouse Anti-beta-Amyloid (CBP7377) | Human; Mouse; Rat | ELISA; IHC-P; IHC-F; ICC; IF |
NAB-BA-P067 | Mouse Anti-beta Amyloid 1-28 Monoclonal Antibody (CBP7379) | Human | ELISA |
NAB2007FY542 | NeuroMab™ Mouse Anti-Alpha Synuclein Monoclonal Antibody (CBP1970) | Human; Mouse; Rat | WB; DB; ICC; IF; ELISA; IHC |
NAB2007FY547 | Rabbit Anti-Alpha Synuclein pSer129 Monoclonal Antibody (CBP1974) | Human; Mouse | ELISA; WB; ICC; IF; IHC |
NRZP-0522-ZP26 | NeuroMab™ Anti-Alpha Synuclein, Mouse Monoclonal Antibody, Clone 3H9 (CBP8679) | Bovine; Chicken; Horse; Human; Mouse; Pig; Rat | WB; ICC |
NRZP-0922-ZP4273 | NeuroMab™ Anti-α/β-Synuclein Antibody, Clone N8958 (CBP15584) | Human; Mouse; Rat | WB; IP; IHC; IF |
NAB-0720-Z6675 | Mouse Anti-PSEN1 Monoclonal Antibody (CBP3397) | Mouse; Rat; Human | IP; IHC-Fr; ICC; IF; WB; ELISA; IHC-P; FC |
NAB-08-PZ1040 | NeuroMab™ Rabbit Anti-Human PSEN1 Monoclonal Antibody (CBP1651) | Human | ICC; IF; FC |
NRP-0422-P2033 | NeuroMab™ Anti-Presenilin 1 Antibody, Clone CB-PC7 | Human; Mouse; Rat | WB; Inhib; Block; In Vitro |
NRZP-1022-ZP3396 | NeuroMab™ Anti-Presenilin 1 BBB Shuttle Antibody, Clone CB-PC7 | Human; Mouse; Rat | WB; Inhib; Block; In Vitro |
NRZP-1222-ZP789 | NeuroMab™ Anti-Aβ Antibody, Clone TAP01 | Human | In Vitro |
NRZP-1222-ZP1037 | NeuroMab™ Anti-Aβ BBB Shuttle Antibody, Clone TAP01 | Human | In Vitro |
NAB2010591LS | NeuroMab™ Mouse Anti-Human Amyloid Beta 1-40 Monoclonal Antibody (CBP2475) | Human | ELISA; IHC; WB; IP |
Research Advances Utilizing the 5xFAD Model
The 5xFAD mouse model serves as a versatile platform for studying the efficacy and safety of potential therapies targeting various aspects of AD pathology. By utilizing the robust phenotype of the 5xFAD mouse, researchers can assess the effects of drug candidates, gene therapies, or lifestyle interventions on amyloid deposition, neuroinflammation, synaptic function, and cognitive performance.
Below are some of the advances in AD research applying the 5xFAD mouse model.
Potential Therapies | Research Advances |
Amyloid Targeting Therapies Study |
|
Neuroinflammatory Modulation |
|
Advancements in the 5xFAD Mouse Model Technology
There have been many advancements in the 5xFAD mouse model technology in recent years, with most focusing on a better understanding of the disease's underlying mechanisms and evaluation of potential therapeutic strategies.
-
Neuroscience imaging technology
Researchers introduced novel ways of visualizing and tracking the development of amyloid plaques in the model's brain. Recent improvements in techniques like multiphoton microscopy and magnetic resonance imaging (MRI) have enabled researchers to monitor the progression of Aβ plaques and subsequent neurodegeneration in real time. Insights into the role of synaptic proteins, neurotransmitter systems, and signaling pathways in ASD pathogenesis. -
Advances in transcriptomics, proteomics, and metabolomics
Notable progress in the realm of molecular biology, which helped enhance our knowledge of the disease's molecular mechanisms. This profound molecular profiling has been instrumental in shedding light on potential therapeutic targets.
Creative Biolabs' unwavering dedication to excellence and innovation ensures that the promise of the 5xFAD model is realized.
Reference
- DeBay, Drew R., et al. "No difference in cerebral perfusion between the wild-type and the 5XFAD mouse model of Alzheimer's disease." Scientific Reports 12.1 (2022): 22174.
- NeuroMab™ Mouse Anti-EFNB2 Monoclonal Antibody (CBP1159) (Cat#: NAB-0720-Z4396)
- NeuroMab™ Anti-pTau Antibody(NRP-0422-P1719) (Cat#: NRP-0422-P1719)
- NeuroMab™ Rabbit Anti-Alpha-synuclein (CBP1631) (Cat#: NAB-08-PZ079)
- NeuroMab™ Anti-Tau Antibody(NRP-0422-P2275) (Cat#: NRP-0422-P2275)
- NeuroMab™ Anti-F-Spondin/SPON1 Antibody, Clone N24875P (CBP11839) (Cat#: NRZP-0822-ZP4740)
- NeuroMab™ Anti-CD20 Antibody(NRP-0422-P1230) (Cat#: NRP-0422-P1230)
- NeuroMab™ Anti-Alpha Synuclein BBB Shuttle Antibody(NRZP-1022-ZP4050) (Cat#: NRZP-1022-ZP4050)
- NeuroMab™ Anti-SEZ6 Antibody(NRP-0422-P517) (Cat#: NRP-0422-P517)
- NeuroMab™ Anti-Tau Antibody(NRP-0422-P2293) (Cat#: NRP-0422-P2293)
- NeuroMab™ Anti-Tau Antibody(NRP-0422-P1683) (Cat#: NRP-0422-P1683)
- Rat Immortalized Retinal Muller Cell Line rMC-1 (Cat#: NCL-2106-S93)
- Human Blood Brain Barrier Model (Cat#: NCL-2103-P187)
- Green Fluorescent Tau SH-SY5Y cell Line (Cat#: NCL2110P219)
- Human Glial (Oligodendrocytic) Hybrid Cell Line (MO3.13) (Cat#: NCL-2108P34)
- Human Brain Microvascular Endothelial Cells (Cat#: NCL-2103-P133)
- Rat Schwann Cells RSC96, Immortalized (Cat#: NCL-2108P21)
- Human Astrocytes (Cat#: NCC20-9PZ01)
- Green Fluorescent Alpha-synuclein SH-SY5Y Cell Line (Cat#: NCL2110P209)
- Mouse Glioma Cell Line GL261-GFP (Cat#: NCL-2108P04)
- Immortalized Human Cerebral Microvascular Endothelial Cells (Cat#: NCL-2108-P020)
- Human Poly ADP ribose polymerase,PARP Assay Kit (Cat#: NRZP-1122-ZP62)
- Beta Amyloid (1-42), Aggregation Kit (Cat#: NRZP-0323-ZP200)
- Human GFAP ELISA Kit [Colorimetric] (Cat#: NPP2011ZP383)
- Human Tau Aggregation Kit (Cat#: NRP-0322-P2173)
- Beta Amyloid (1-40), Aggregation Kit (Cat#: NRZP-0323-ZP199)
- Alpha Synuclein Aggregation Kit (Cat#: NRZP-1122-ZP15)
- Amyloid beta 1-42 Kit (Cat#: NRP-0322-P2170)
- Alpha-Synuclein Aggregation Assay Kit (Cat#: NRZP-1122-ZP37)
- pAAV-syn-FLEX-jGCaMP8s-WPRE (Cat#: NTA-2106-P066)
- pAAV-EF1a-DIO-EGFP-WPRE (Cat#: NTA-2012AD-P285)
- pAAV-syn-jGCaMP8s-WPRE (Cat#: NTA-2106-P063)
- AAV2/9-hSyn-Flpo-EGFP-WPRE-pA (Cat#: NTA-2012-ZP149)
- pAAV-hSyn-DIO-XCaMP-R-WPRE (Cat#: NTA-2012AD-P508)
- AAV-EF1a-mCherry-flex-dtA (Cat#: NRZP-0622-ZP616)
- AAV2 Full Capsids, Reference Standards (Cat#: NTC2101070CR)
- PRV-CAG-EGFP (Cat#: NTA-2011-ZP14)
- rAAV-E-SARE-Cre-ERT2-PEST-WPRE-hGH polyA (Cat#: NTA-2010-TT342)
- AAV-mDLX-CRE-tdTomato (Cat#: NRZP-0622-ZP721)
- Rat Parkinson disease (autosomal recessive, juvenile) 2, parkin (Park2) (NM_020093) ORF clone/lentiviral particle, Myc-DDK Tagged (Cat#: NEP-0621-R0041)
- Human presenilin 1 (PSEN1), transcript variant 2 (NM_007318) ORF clone, TurboGFP Tagged (Cat#: NEP-0421-R0140)
- Human huntingtin (HTT) (NM_002111) ORF clone, Myc-DDK Tagged (Cat#: NEP-0521-R0497)
- Mouse SOD1 shRNA Silencing Adenovirus (Cat#: NV-2106-P14)
- Lenti of Mouse synuclein, alpha (Snca) transcript variant (NM_001042451) ORF clone, mGFP Tagged (Cat#: NEP-0521-R0864)
- Tau Antisense Oligonucleotide (IONIS-MAPTRx) (Cat#: NV-2106-P29)
- Human apolipoprotein E (APOE) (NM_000041) ORF clone, Untagged (Cat#: NEP-0421-R0232)
- Lenti of Human TAR DNA binding protein (TARDBP) (NM_007375) ORF clone, mGFP Tagged (Cat#: NEP-0521-R0832)
- Human superoxide dismutase 3, extracellular (SOD3) (NM_003102) ORF clone, Untagged (Cat#: NEP-0521-R0808)
- Human huntingtin-associated protein 1 (HAP1) transcript variant 2 (NM_177977) ORF clone, Myc-DDK Tagged (Cat#: NEP-0521-R0676)
- NeuroBiologics™ Mouse Cerebrospinal Fluid (Cat#: NRZP-0822-ZP497)
- NeuroBiologics™ Human Cerebrospinal Fluid (Cat#: NRZP-0822-ZP491)
- NeuroBiologics™ Monkey Cerebrospinal Fluid (Cat#: NRZP-0822-ZP495)
- NeuroBiologics™ Pig Cerebrospinal Fluid (Cat#: NRZP-0822-ZP498)
- NeuroBiologics™ Rat Cerebrospinal Fluid (Cat#: NRZP-0822-ZP496)
- NeuroPro™ Anti-TNFR BBB Shuttle Protein (Cat#: NRZP-0423-ZP501)
- NeuroPro™ Anti-Erythropoietin BBB Shuttle Protein (Cat#: NRZP-0423-ZP499)
- NeuroPro™ Anti-PON1 BBB Shuttle Protein (Cat#: NRZP-0423-ZP507)
- NeuroPro™ Anti-SGSH BBB Shuttle Protein (Cat#: NRZP-0423-ZP505)
- NeuroPro™ Anti-IDUA BBB Shuttle Protein (Cat#: NRZP-0423-ZP502)
- NeuroPro™ Anti-EPO BBB Shuttle Protein (Cat#: NRZP-0423-ZP508)
- NeuroPro™ Anti-GDNF BBB Shuttle Protein (Cat#: NRZP-0423-ZP500)
- NeuroPro™ Anti-NAGLU BBB Shuttle Protein (Cat#: NRZP-0423-ZP506)
- NeuroPro™ Anti-IDS BBB Shuttle Protein (Cat#: NRZP-0423-ZP503)
- NeuroPro™ Anti-TNFR BBB Shuttle Protein (Cat#: NRZP-0423-ZP510)